Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
about
Nucleases in homologous recombination as targets for cancer therapyPARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress.Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In VitroYU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitorsTriapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP InhibitionEmbracing synthetic lethality of novel anticancer therapies.Synthesis and Evaluation of New Benzodioxole- Based Thiosemicarbazone Derivatives as Potential Antitumor Agents.There and Back Again: The Middle Earth of DNA Repair.Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer.Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
P2860
Q26822478-E7635D3B-1099-4114-8FE8-39F9559B2AEDQ33843183-9A2849BB-F845-4D6A-BDDC-CF7455DF6822Q34178561-34680E8D-04D3-4C96-A78F-957395111A28Q35600390-3EB9F20B-253A-4437-ABAE-69853D42E4FBQ35676066-9C61F037-D801-4BDF-BCC5-0DBBD9C09218Q36087979-6E9BD931-575E-4F88-866F-193976423142Q36946591-6D86AD96-C0CE-4A54-9A38-74422A4435C1Q37174956-D3F345F3-3CCF-469F-85CE-1E70E147FE63Q37665228-90328969-F001-4528-9A72-7DB18F49D9C8Q38324762-EB2C2E30-173D-43A2-A883-81F77F3A64AFQ38554530-A8EF006D-23A4-4729-9015-9F9F1D37CAB3Q38729281-9958C863-918A-4694-BF9D-985D2BD122A4Q41653516-84FBDA18-50A6-4248-AE20-113C36312040Q50106233-397B54B1-9211-46B6-98A9-BD742961E696Q58795530-23D0FA02-6A08-4619-9031-CC1BE7694D58
P2860
Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Triapine disrupts CtIP-mediate ...... and topoisomerase inhibitors.
@en
Triapine disrupts CtIP-mediate ...... and topoisomerase inhibitors.
@nl
type
label
Triapine disrupts CtIP-mediate ...... and topoisomerase inhibitors.
@en
Triapine disrupts CtIP-mediate ...... and topoisomerase inhibitors.
@nl
prefLabel
Triapine disrupts CtIP-mediate ...... and topoisomerase inhibitors.
@en
Triapine disrupts CtIP-mediate ...... and topoisomerase inhibitors.
@nl
P2093
P2860
P1476
Triapine disrupts CtIP-mediate ...... and topoisomerase inhibitors.
@en
P2093
Alan C Sartorelli
Elena S Ratner
Margaret E Whicker
Yashang Lee
Z Ping Lin
P2860
P304
P356
10.1158/1541-7786.MCR-13-0480
P577
2014-01-10T00:00:00Z